Business, energy, technology, markets and global industry news from Business News Today

Bausch + Lomb

PharmaDeviceNews Bausch + Lomb
Representative image of RNAi drug discovery research in a biotechnology laboratory. City Therapeutics’ $99.5 million Series B financing puts next-generation RNA interference therapies, including CITY-FXI and CITY-RBP4, in sharper focus as the field expands beyond liver-targeted medicines.
Pharma & Biotech

City Therapeutics raises $99.5m as CITY-FXI and CITY-RBP4 head toward key tests

City Therapeutics has fresh capital, but RNAi’s next test is tissue delivery. See why CITY-FXI and CITY-RBP4 matter now.

Read More
Medical Devices & Diagnostics

Why Bausch + Lomb’s ASCRS 2026 data slate matters for premium IOL competition and dry eye care

Find out why Bausch + Lomb’s ASCRS 2026 data package could reshape competition in cataract surgery, dry eye care, and ophthalmology platforms.

Read More